We attempted to analyze the effects of KIR/HLA mismatch on clinical outcomes on transplant outcomes using the cohort of 54 AML patients who received a haplo-HSCT with PTCy. This evidence concerns the gene KIR3DL1 and acute myeloid leukemia.